MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Anti-synuclein alpha antibodies and IL-1β at Parkinson Disease (PD).

A. Boika, V. Ponomarev, H. Ivanchik (Minsk, Belarus)

Meeting: 2017 International Congress

Abstract Number: 576

Keywords: Inflammation, Parkinsonism

Session Information

Date: Tuesday, June 6, 2017

Session Title: Parkinson's Disease: Pathophysiology

Session Time: 1:45pm-3:15pm

Location: Exhibit Hall C

Objective: Determine a correlation between the levels of anti-synuclein alpha antibodies and IL-1β at serum and CSF of patients with PD.

Background: PD is a progressive neurodegenerative disorder with impact of immune reactions on the pathogenesis. Recent studies revealed that abnormal aggregation and accumulation of synuclein has implicated in PD development. Higher level of SNCA at plasma and lower concentration of SNCA at CSF than at healthy control were revealed at PD. IL-1β plays an important role at regulation of immune and inflammatory responses.

Methods: Serum and cerebrospinal fluids (CSF) were obtained from 31 patient with PD (M:F=0,94:1; age=63,7±10,3 SD) – main group (MG) and 8 subject (M:F=3:1; age= 64±8,2 SD) with planned minor surgical operations under peridural anesthesia (herniotomy or pelvic plastic) – control group (CG). Non-parametric methods of statistical analysis were used. Investigation was approved by local ethic committee. All subjects signed informed consent form before including in the study. Anti-synuclein alpha antibodies (SNCA) and IL-1β concentration were determined using ELISA kits (Anti-SNCA Cloud-Clone Corp., US and Vector-Best, Russia, respectively).

Results: Anti-synuclein alpha antibodies at serum were detected at all samples of MG and at 6 (75%) samples of CG. At CSF positive results were at 10 (32,3%) samples of MG and only at 1 (12,5%) sample of CG. IL-1β was detected at all samples of both groups. Median levels of anti-synuclein alpha antibodies were at MG (serum – 5,06 ng/ml [2,82; 8,82], CSF – 0,0 ng/ml [0,0; 0,61] and at CG (serum – 3,29 ng/ml [0,34; 3,84], CSF – the single result was 0,61 ng/ml). Median levels of IL-1β were at MG (serum – 2,04 pg/ml [1,65; 3,04], CSF – 2,48 pg/ml [2,09; 2,95] and at CG (serum – 2,68 pg/ml [2,1; 2,98], CSF – 2,97 pg/ml [2,42; 4,48]. Only difference for anti-synuclein alpha antibodies at serum between MG and CG was statistically significant (Mann-Whitney test, p=0,02). No correlation was found between serum levels of anti-synuclein alpha antibodies and IL-1β of MG with use of Spearman Rank Order Correlation (R=0,18, p=0,3).

Conclusions: The level of anti-synuclein alpha antibodies may be useful for the diagnose of PD. Level of anti-synuclein alpha antibodies is not connected with non specific immune and inflammatory response.

To cite this abstract in AMA style:

A. Boika, V. Ponomarev, H. Ivanchik. Anti-synuclein alpha antibodies and IL-1β at Parkinson Disease (PD). [abstract]. Mov Disord. 2017; 32 (suppl 2). https://www.mdsabstracts.org/abstract/anti-synuclein-alpha-antibodies-and-il-1%ce%b2-at-parkinson-disease-pd/. Accessed May 9, 2025.
  • Tweet
  • Email
  • Print

« Back to 2017 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/anti-synuclein-alpha-antibodies-and-il-1%ce%b2-at-parkinson-disease-pd/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • The hardest symptoms that bother patients with Parkinson's disease
  • The clinical effects of mucuna and green tea in combination with levodopa-benserazide in advanced Parkinson's disease: Experience from a case report
  • To be or not to bupropion: a drug-induced parkinsonism?
  • #25822 (not found)
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Restless Leg Syndrome After Propranolol Intake: A Single Case
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley